^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
QP34563457
i
Other names: QP34563457, trastuzumab/pertuzumab/IL-15, T-mab/P-mab/IL-15, trastuzumab/pertuzumab/IL-15 trifunctional fusion protein
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Viva Biotech
Drug class:
HER2 inhibitor, IL-15R agonist
Related drugs:
3years
[VIRTUAL] Preclinical evaluation of trastuzumab/pertuzumab/IL-15, a new trifunctional fusion protein, for HER2 positive cancer therapy (AACR 2021)
Our data demonstrated that the trifunctional fusion protein QP34563457 have higher biological activity than single anti-HER2 antibody T-mab or P-mab and their combination, suggesting a more effective HER2 (+) cancer treatment potential. In combination with a dosing matching IL-15 activity, QP34563457 is expected to engage immune cells in a HER2 (+) tumor targeted manner and exhibit synergistic effects by bispecific targeting on HER2 (+) tumors as well. The yield and physiochemical properties of QP34563457 is up to the industrial production standard.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • IL2 (Interleukin 2)
|
HER-2 positive
|
QP34563457
Share via
